HANDI hopes that you find these pain management resources helpful as we approach the busy holiday season!
The Genentech therapy has been approved for routine prophylaxis in adults and children with or without factor VIII inhibitors.
The National Hemophilia Foundation (NHF) is pleased to announce the 2018 NHF-Shire Clinical Fellowship award recipients.
HANDI hopes that you find these resources to be helpful and informative as you or a family member face a major life transition.
Watch this video to learn how copay accumulator adjustments affect patients requiring specialty medications with no generic alternatives.
It's not too late to provide your feedback and help drive the critical direction of inhibitor research. Deadline is November 12th!
In this study, researchers uncovered a relatively high rate of established risk factor amongst young people hemophilia, then discuss possible interventions for prevention.
By accessing this activity healthcare providers will increase their knowledge of the potential role of gene therapy to address challenges in current hemophilia treatment.
Bayer received FDA approval for new extended half-life hemophilia A product for patients 12 yrs and older.
The new vial size will reduce the reconstitution time that was needed to prepare multiple vials for a similar dose.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car